#JPM20: Five years after first PCSK9, Novartis goes for win as Sanofi moves on, Amgen salvages what's left
SAN FRANCISCO — Sanofi CEO Paul Hudson spent zero seconds of his presentation talking about a cardiovascular drug his company spent years developing.
Robert Bradway of Amgen, the company whose rival product was so formidable Sanofi and their partner Regeneron spent $67.5 million on a priority review voucher to get theirs approved faster, barely touched on the drug. “We’ve made considerable progress during the course of the year on improving access to Repatha,” Bradway said at his presentation, glossing on the company’s deep struggles to sell a drug once billed as a potential megablockbuster.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.